Back
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.
Journal article

The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.

  • Ascierto PA Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Via Mariano Semmola, 80131, Naples, Italy. paolo.ascierto@gmail.com.
  • Agarwala SS Temple University School of Medicine, Philadelphia, PA, USA.
  • Eggermont A Princess Máxima Center Research Directorate, CS, 3584 CS, Utrecht, The Netherlands.
  • Gershenwald JE Department of Surgical Oncology and Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Grob JJ Hopital de la Timone, Aix-Marseille University, Marseille, France.
  • Hamid O Angeles Clinic & Research Institute, Santa Monica, CA, USA.
  • Michielin O Oncology Service, Precision Oncology Center, Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
  • Postow M Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  • Puzanov I Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Zarour HM Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
  • Caracò C Department Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.
  • Testori A Dermatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Show more…
  • 2020-04-18
Published in:
  • Journal of translational medicine. - 2020
Adjuvant
Anti-CTLA-4
Anti-PD-1
BRAF inhibitor
MEK inhibitor
Melanoma
Neoadjuvant
Staging immunotherapy
Targeted therapy
English The Great Debate session at the 2019 Melanoma Bridge congress (December 5-7, Naples, Italy) featured counterpoint views from experts on five topical issues in melanoma. These were whether to choose local intratumoral treatment or systemic treatment, whether patients with stage IIIA melanoma require adjuvant therapy or not, whether treatment is better changed at disease progression or during stable disease, whether adoptive cell transfer (ACT) therapy is more appropriate used before or in combination with checkpoint inhibition therapy, and whether treatment can be stopped while the patient is still on response. As was the case for previous meetings, the debates were assigned by meeting Chairs. As such, positions taken by each of the melanoma experts during the debates may not have reflected their respective personal approach.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/44572
Statistics
Document views: 37 File downloads: